Mylan's Nebivolol NDA User Fee Date Extended To May 31

Three-month delay means the beta blocker's user fee deadline will no longer coincide with the Feb. 28 "walk-away" date for Mylan's acquisition of King. Extension stems from recent submission "of an additional presentation of already submitted data from the nebivolol NDA," Mylan says.